STP705
As of the edition of 20 October 2026, STP705 is a drug known only by a code name: stopped in 2022; acts on PTGS2 and TGFB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Code name only
- Registered trials
- 8, 1 stopped early
- Disease areas
- Cancer; Digestive system; Nutrition and metabolism; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 6 | 5 | 0 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sirnaomics | Lead sponsor of trials | 2019 to now |